Affinia Therapeutics engineers novel adeno-associated virus (AAV) capsids to create gene therapies that more selectively target heart and skeletal muscle while reducing liver exposure. Its lead candidate, AFTX-201, employs a proprietary cardiotropic capsid to deliver a fully human BAG3 transgene for the treatment of BAG3 dilated cardiomyopathy (DCM), a life-threatening inherited heart disease affecting more than 70,000 patients across the U.S., Europe and the U.K. Preclinical studies showed that AFTX-201 restored cardiac function in animal models where conventional capsids failed at the same dose. The company plans to submit an IND for AFTX-201 in Q4 2025 and, pending FDA acceptance, begin a Phase 1/2 UPBEAT trial in Q1 2026. Affinia’s generative-AI discovery platform is also being applied to build a broader pipeline of gene therapies for additional devastating cardiovascular and neurological indications. The newly announced $40 million Series C financing extends the company’s runway to support these clinical and pipeline milestones.

Total raised

$210M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2025